Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Actavis Announces OxyContin® Patent Challenge Settlement to Action-Packed Animated Series Max Steel™ Premieres Monday, March 25, at 4PM (ET/PT)

This site contains about 58,903 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36   37   38   39   40   50   60   70   80   90   100   110   120   200   300   400   500   600   700   800   900   1,000   1,964 

2013/4/26
Actavis Announces OxyContin® Patent Challenge Settlement
PARSIPPANY, N.J. , April 26, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , a leading specialty pharmaceutical company, today announced that it has entered into an agreement with Purdue Pharma to settle all outstanding patent litigation related to Actavis' generic version of the currently marketed abuse-deterrent formulation of OxyContin ® .
View more Actavis Announces OxyContin® Patent Challenge Settlement analysis
Sign-up for Actavis Announces OxyContin® Patent Challenge Settlement investment picks
2013/4/3
Actavis Confirms Court Issues TRO Related to Generic Pulmicort RESPULES® Distribution
PARSIPPANY, N.J. , April 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has granted a motion by AstraZeneca seeking a temporary restraining order (TRO) to prevent Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES ® (budesonide inhalation suspension) 0.25, 0.5 mg products.
View more Actavis Confirms Court Issues TRO Related to Generic Pulmicort RESPULES® Distribution analysis
Sign-up for Actavis Confirms Court Issues TRO Related to Generic Pulmicort RESPULES® Distribution investment picks
2013/5/9
Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit
PARSIPPANY, N.J. , May 9, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the Southern District of Florida has found United States Patent No.
View more Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit analysis
Sign-up for Actavis Confirms District Court Ruling In Generic Lialda® Patent Suit investment picks
2013/4/1
Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit
PARSIPPANY, N.J. , April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has ruled that Actavis' generic version of AstraZeneca's Pulmicort RESPULES ® (budesonide inhalation suspension) 0.25, 0.5 mg, and 1 mg  vials do not infringe United States Patent No.
View more Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit analysis
Sign-up for Actavis Confirms Favorable Ruling In Generic Pulmicort RESPULES® Patent Suit investment picks
2013/4/16
Actavis Confirms Favorable Ruling in Generic Yaz® Patent Suit
PARSIPPANY, N.J. , April 16, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has re-launched Vestura™ (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz ® oral contraceptive product, following a ruling from the United States Court of Appeals for the Federal Circuit that United States Patent No.
View more Actavis Confirms Favorable Ruling in Generic Yaz® Patent Suit analysis
Sign-up for Actavis Confirms Favorable Ruling in Generic Yaz® Patent Suit investment picks
2013/4/1
Actavis Confirms Generic AndroGel® 1.62% Patent Challenge
PARSIPPANY, N.J. , April 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1.62%.  Actavis' ANDA product is a generic version of AbbVie Inc.'s AndroGel ® 1.62%, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
View more Actavis Confirms Generic AndroGel® 1.62% Patent Challenge analysis
Sign-up for Actavis Confirms Generic AndroGel® 1.62% Patent Challenge investment picks
2013/3/8
Actavis Confirms Generic Exelon® Patch Patent Challenge
PARSIPPANY, N.J. , March 8, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed with the U.S. Food and Drug Administration (FDA) an amendment to its Abbreviated New Drug Application (ANDA) for Rivastigmine Transdermal System to include the 13.3 mg per 24 hours dosage strength.
View more Actavis Confirms Generic Exelon® Patch Patent Challenge analysis
Sign-up for Actavis Confirms Generic Exelon® Patch Patent Challenge investment picks
2013/3/1
Actavis Confirms Generic Fortesta® Patent Challenge
PARSIPPANY, N.J. , March 1, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone gel 10mg/0.5g.  Actavis' ANDA product is a generic version of Endo Pharmaceuticals' Fortesta ® , which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
View more Actavis Confirms Generic Fortesta® Patent Challenge analysis
Sign-up for Actavis Confirms Generic Fortesta® Patent Challenge investment picks
2013/5/2
Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
- 21% Increase in Q1 2013 Non-GAAP EPS to $1.99; GAAP Earnings (Loss) Per Share of $(0.79) - - 26% Increase in Adjusted EBITDA to $464 million - - Company Increases 2013 Forecast - PARSIPPANY, N.J. , May 2, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 24 percent to $1.90 billion for the first quarter 2013, compared to $1.52 billion in the first quarter 2012.
View more Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion analysis
Sign-up for Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion investment picks
2013/2/19
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
- 26% Increase in Full Year 2012 Non-GAAP EPS to $6.00; GAAP EPS $0.76 - - Fourth Quarter 2012 Net Revenue of $1.75 Billion - - Fourth Quarter 2012 Non-GAAP EPS of $1.59; GAAP EPS $0.21 - - Company Reaffirms 2013 Forecast - PARSIPPANY, N.J. , Feb.
View more Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion analysis
Sign-up for Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion investment picks
2013/3/25
Actavis Reaches Agreement with AstraZeneca to Launch a Generic Version of Crestor® in 2016
- Launch to occur 67 days ahead of expiry of pediatric exclusivity - PARSIPPANY, N.J. , March 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor ® tablets, as well as Actavis' rosuvastatin zinc alternate salt product.
View more Actavis Reaches Agreement with AstraZeneca to Launch a Generic Version of Crestor® in 2016 analysis
Sign-up for Actavis Reaches Agreement with AstraZeneca to Launch a Generic Version of Crestor® in 2016 investment picks
2013/4/25
Actavis Reaches Agreement with Shire to Launch a Generic Version of Intuniv® in December 2014
- 180 Days of Exclusivity - PARSIPPANY, N.J. , April 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic version of INTUNIV ® (guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder.
View more Actavis Reaches Agreement with Shire to Launch a Generic Version of Intuniv® in December 2014 analysis
Sign-up for Actavis Reaches Agreement with Shire to Launch a Generic Version of Intuniv® in December 2014 investment picks
2013/4/10
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® Canada NewsWire PARSIPPANY, N.J. and MONTREAL , April 10, 2013 /CNW/ - Actavis, Inc. (NYSE: ACT) , and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) , today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant Pharmaceuticals International, Inc., resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application (ANDA) for Clindamycin and Tretinoin Gel, a generic version of Ziana ® , as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara ® .
View more Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® analysis
Sign-up for Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® investment picks
2013/4/10
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®
PARSIPPANY, N.J. and MONTREAL, Quebec , April 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) , today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant Pharmaceuticals International, Inc., resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application (ANDA) for Clindamycin and Tretinoin Gel, a generic version of Ziana ® , as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara ® .
View more Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® analysis
Sign-up for Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® investment picks
2013/2/14
Actavis Reaches Settlement with Mallinckrodt Over Exalgo® 32 mg Dosage Strength
PARSIPPANY, N.J , Feb.
View more Actavis Reaches Settlement with Mallinckrodt Over Exalgo® 32 mg Dosage Strength analysis
Sign-up for Actavis Reaches Settlement with Mallinckrodt Over Exalgo® 32 mg Dosage Strength investment picks
2013/4/3
Actavis Temporarily Enjoined From Selling Generic of AstraZeneca's Pulmicort Respules
Actavis Inc. (ACT) confirmed a New Jersey court has granted a motion from AstraZeneca PLC (AZN) seeking a temporary restraining order to prevent Actavis from further distributing its generic version of asthma treatment Pulmicort Respules.
View more Actavis Temporarily Enjoined From Selling Generic of AstraZeneca's Pulmicort Respules analysis
Sign-up for Actavis Temporarily Enjoined From Selling Generic of AstraZeneca's Pulmicort Respules investment picks
2013/5/3
Actavis to Host Annual Meeting of Stockholders on May 10, 2013
PARSIPPANY, N.J. , May 3, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , today announced that the Company will host its 2013 Annual Meeting of Stockholders on Friday, May 10, 2013 beginning at 8:30 AM Eastern Daylight Time .
View more Actavis to Host Annual Meeting of Stockholders on May 10, 2013 analysis
Sign-up for Actavis to Host Annual Meeting of Stockholders on May 10, 2013 investment picks
2013/4/10
Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
PARSIPPANY, N.J. , April 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , announced today that it intends to release first quarter 2013 financial results on Thursday, May 2, 2013 , prior to the open of the U.S. financial markets.
View more Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast analysis
Sign-up for Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast investment picks
2013/2/1
Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
PARSIPPANY, N.J. , Feb.
View more Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast analysis
Sign-up for Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast investment picks
2013/5/7
Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
PARSIPPANY, N.J. , May 7, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) , a leading specialty pharmaceutical company, announced today that Paul Bisaro , Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada .
View more Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference analysis
Sign-up for Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference investment picks
2013/2/27
Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
PARSIPPANY, N.J. , Feb.
View more Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference analysis
Sign-up for Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference investment picks
2013/2/20
Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
PARSIPPANY, N.J. , Feb.
View more Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference analysis
Sign-up for Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference investment picks
2013/2/12
Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
PARSIPPANY, N.J. , Feb.
View more Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference analysis
Sign-up for Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference investment picks
2013/2/25
Actavis' Generic Suboxone® Receives FDA Approval
PARSIPPANY, N.J. , Feb.
View more Actavis' Generic Suboxone® Receives FDA Approval analysis
Sign-up for Actavis' Generic Suboxone® Receives FDA Approval investment picks
2013/1/28
Actian and Pervasive Software Merge to Create a Disruptive Force in Big Data
Actian Corp.
View more Actian and Pervasive Software Merge to Create a Disruptive Force in Big Data analysis
Sign-up for Actian and Pervasive Software Merge to Create a Disruptive Force in Big Data investment picks
2013/4/11
Actian Corporation and Pervasive Software Unite to Take Action on Big Data
Actian Corp.
View more Actian Corporation and Pervasive Software Unite to Take Action on Big Data analysis
Sign-up for Actian Corporation and Pervasive Software Unite to Take Action on Big Data investment picks
2013/2/6
Actiance to Advise Attendees at the 2013 Asset-Based Capital Conference on Successfully Leveraging Social Media
http://media.marketwire.com/attachments/201211/107531_ScreenShot2012-11-29at1.45.09PM.png http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982520&ProfileId=051205&sourceType=1 BELMONT, CA --
View more Actiance to Advise Attendees at the 2013 Asset-Based Capital Conference on Successfully Leveraging Social Media analysis
Sign-up for Actiance to Advise Attendees at the 2013 Asset-Based Capital Conference on Successfully Leveraging Social Media investment picks
2013/1/30
Actiance to Present on Successful Social Media Engagement Strategies at the 2013 Raymond James Compliance Roundtable
http://media.marketwire.com/attachments/201211/107531_ScreenShot2012-11-29at1.45.09PM.png http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=979841&ProfileId=051205&sourceType=1 BELMONT, CA --
View more Actiance to Present on Successful Social Media Engagement Strategies at the 2013 Raymond James Compliance Roundtable analysis
Sign-up for Actiance to Present on Successful Social Media Engagement Strategies at the 2013 Raymond James Compliance Roundtable investment picks
2013/3/4
Action for Healthy Kids(R) and Kellogg's(R) Celebrate the Power of School Breakfast With Schools Across the Country
CHICAGO, March 4, 2013 (GLOBE NEWSWIRE) -- Throughout March, Action for Healthy Kids® and Kellogg's® will help schools around the United States celebrate the powerful impact of school breakfast on students with family and community breakfast events made possible by the Kellogg's Share Breakfast ™ program.
View more Action for Healthy Kids(R) and Kellogg's(R) Celebrate the Power of School Breakfast With Schools Across the Country analysis
Sign-up for Action for Healthy Kids(R) and Kellogg's(R) Celebrate the Power of School Breakfast With Schools Across the Country investment picks
2013/3/21
Action-Packed Animated Series Max Steel™ Premieres Monday, March 25, at 4PM (ET/PT)
Mattel (NASDAQ:MAT) brings its latest action hero property to boys across the country with Max Steel™, a new CGI animated TV series premiering on Monday, March 25 at 4 p.m. (ET/PT) on Disney XD.
View more Action-Packed Animated Series Max Steel™ Premieres Monday, March 25, at 4PM (ET/PT) analysis
Sign-up for Action-Packed Animated Series Max Steel™ Premieres Monday, March 25, at 4PM (ET/PT) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Actavis Announces OxyContin® Patent Challenge Settlement to Action-Packed Animated Series Max Steel™ Premieres Monday, March 25, at 4PM (ET/PT)
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.